Destiny Pharma PLC Director Dealing (5504B)
10 Junio 2021 - 11:00AM
UK Regulatory
TIDMDEST
RNS Number : 5504B
Destiny Pharma PLC
10 June 2021
Destiny Pharma plc
("Destiny Pharma" or the "Company")
Director Dealing
Destiny Pharma plc (AIM: DEST) a clinical stage innovative
biotechnology company focused on the development of novel medicines
that can prevent life threatening infections, announces that it was
notified on 10 June 2021 that on that same day, Dr William Love,
Chief Scientific Officer of the Company, sold 350,000 ordinary
shares of 1 pence in the Company ("Ordinary Shares") at a price of
120 pence.
Following the sale, Dr William Love's beneficial interest in the
Company is 6,509,500 Ordinary Shares, representing 10.87 per cent.
of the total issued share capital. Dr Love confirms that he does
not intend to sell any further Ordinary Shares for the foreseeable
future, that is until 2023 at the earliest.
Enquiries:
+44 (0) 1273 704
Destiny Pharma plc 440
Neil Clark, CEO
Shaun Claydon, CFO
finnCap Limited - Nominated Adviser and Joint
Broker +44 (0) 20 7220 0500
Geoff Nash / Kate Bannatyne (Corporate Finance)
Alice Lane (ECM)
WG Partners LLP - Joint Broker +44 (0) 20 3705 9330
Nigel Barnes / Claes Spång / Nigel Birks
Optimum Strategic Communications +44 (0) 203 174 1789
Mary Clark / Shabnam Bashir / Manel Mateus
About Destiny Pharma
Destiny Pharma is a clinical stage, innovative biotechnology
company focused on the development of novel medicines that can
prevent life-threatening infections. Its pipeline has novel
microbiome-based biotherapeutics and XF drug clinical assets
including NTCD-M3, a Phase 3 ready treatment for the prevention of
C. difficile infection (CDI) recurrence which is the leading cause
of hospital acquired infection in the US and also XF-73 nasal gel,
which is in a Phase 2b clinical trial targeting the prevention of
post-surgical Staphylococcal hospital including MRSA. It is also
co-developing SPOR-COV, a novel, biotherapeutic product for the
prevention of COVID-19 and other viral respiratory infections and
has earlier grant funded XF research projects.
For further information, please visit
https://www.destinypharma.com
This announcement contains inside information for the purposes
of Article 7 of the Market Abuse Regulation (EU) 596/2014 as it
forms part of UK domestic law by virtue of the European Union
(Withdrawal) Act 2018 ("MAR"), and is disclosed in accordance with
the company's obligations under Article 17 of MAR.
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely
associated with them
1. Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Dr William Love
------------------------------- --------------------------------------
2. Reason for the Notification
-----------------------------------------------------------------------
a) Position/status Chief Scientific Officer
------------------------------- --------------------------------------
b) Initial notification/Amendment Initial Notification
------------------------------- --------------------------------------
3. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-----------------------------------------------------------------------
a) Name Destiny Pharma plc
------------------------------- --------------------------------------
b) LEI 213800O9WH9Z38EHAC95
------------------------------- --------------------------------------
4. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
-----------------------------------------------------------------------
a) Description of the Ordinary shares of 1p each ("Ordinary
Financial instrument, Shares")
type of instrument
------------------------------- --------------------------------------
Identification code DEST GB00BDHSP575
------------------------------- --------------------------------------
b) Nature of the transaction Sale of Ordinary Shares
------------------------------- --------------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
Sold 120 pence 350,000
----------- ----------
------------------------------- --------------------------------------
d) Aggregated information:
* Aggregated volume See 4c) above
* Price
------------------------------- --------------------------------------
e) Date of the transaction 10 June 2021
------------------------------- --------------------------------------
f) Place of the transaction London Stock Exchange, AIM Market
(XLON)
------------------------------- --------------------------------------
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHFLFEERLIILIL
(END) Dow Jones Newswires
June 10, 2021 12:00 ET (16:00 GMT)
Destiny Pharma (LSE:DEST)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Destiny Pharma (LSE:DEST)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024